This is a reprint of abstract #35 of the Eighth International Conference of Society for Integrative Oncology (SIO) - November 2011, Cleveland, Ohio.
Hongsheng Lin, China Academy of Chinese Medicines; Jie Li, China Academy of Chinese Medicines; Wei Hou, China Academy of Chinese Medicines
Purpose: Hand-Foot Syndrome (HFS) is a common side effect of several chemotherapies such as 5-FU and its derivatives. Literature shows 45-68% cancer patients receiving oral capecitabine treatment developed HFS; 34% of them had severe HFS to a point where doctors had to reduce their chemotherapy dose or temporarily stop chemotherapy. Chinese herbal medicine JDXZF (including herba dictamni cortex, etc.) is an empirical formula. The preliminary study has shown JDXZF is effective for relieving pain and helpful for the skin lesion on treating HFS. JDXZO is an advanced Chinese herbal extract cream based on JDXZF for easy use. No side effect such as allergy or infection related to JDXZO was found. This randomized, double blind, placebo-controlled study aims to evaluate the safety and efficacy of JDXZO for HFS.
Methods: Cancer patients with HFS grade >= 1 (NCI-CTCAE version 3.0) caused by capecitabine were eligible. Patients received oral capecitabine twice daily on days 1-14. Capecitabine chemotherapy was repeated every 21 days in the absence of disease progression or unacceptable toxicity. Patients with same HFS grade level were randomized to cream A or cream B arm and instructed to gently apply cream on affected areas twice daily for two weeks. Patients’ HFS grades were assessed before and after treatment.
Evaluation criteria: CR as symptoms disappear completely, PR as grade decreases more than one level, PD as symptoms or grade increase, total response rate as CR + PR. Time relative to HFS grade level decrease was counted in days.
Results: 31 cancer patients entered and received 2-6 courses of capecitabine. The medium time-to-develop HFS was week 2 of capecitabine chemotherapy. A total of 83 HFS cases (if the same patients developed HFS multiple times during chemotherapy they were counted separately) were evaluated and 39 were grade 1, 34 were grade 2 and 10 were grade 3. HFS cases in cream A or B arm were 42 and 41, respectively. There was no statistical difference between the two arms in gender, age and cancer type (P>0.05).
Cream A arm CR was 11.9% (5/42), PR was 28.6% (12/42), PD was 59.5% (25/42), total response rate was 40.5%. CR of cream B arm was 36.6% (15/41), PR was 46.3% (19/41), PD was 19.5% (8/41), and total response rate was 82.9%. Improvement of skin lesion toxicity mainly included relief of numbness, dermatitis, desquamation and ulceration pain on the palms or soles. The average treatment time for grade level decrease in cream B arm was 1.7 days shorter than that of cream A arm, it was 2.9 days shorter in grade 3 patients(P
Conclusion: JDXZO was superior to placebo in improving HFS. Cream A and Cream B were provided by Unitech Medical®